Resistance to azolic compounds in clinical Trichophyton spp. strains;Resistencia a compuestos azólicos de aislamientos clínicos de Trichophyton spp.

Revista Iberoamericana de Micologia

Volumn 24, Issue 4, 2007, Pages 320-322

  Méndez Tovar, Luis Javier ^a,c   Manzano Gayosso, Patricia ^b   Velásquez Hernández, Verónica ^a   Millan Chiu, Blanca ^b   Hernández Hernández, Francisca ^b   Mondragón González, Rafael ^a   López Martínez, Rubén ^b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c CSPI Coahuila   (Mexico)

Author keywords

Antifungal drugs; Antifungal resistance; Dermatophytosis; Fluconazole; Trichophyton

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DERMATOMYCOSIS; FUNGAL VIRULENCE; FUNGUS ISOLATION; LABORATORY TEST; NONHUMAN; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS;

TRICHOPHYTON; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS;

EID: 38349193737     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(07)70065-7     Document Type: Article

References (13)

1. Bradley MC, Leidich S, Isham N, Iewsky BE, Ghannoum MA. Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of toenail. Mycoses 1999; 43(suppl 2): 105-110.
2. Clinical Laboratory Standards Institute (CLSI). National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
3. Consenso Nacional de Prevención, Diagnóstico y Tratamiento de Micosis Superficiales. Tercera Revisión 2006. Editado por Bayer de México/Facultad de Medicina, UNAM. ISBN: 970-32-3006-7.
4. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: 32-36.
5. Fernández-Torres B, Carrillo-Muñoz A, Ortopeda M, Pujol I, Pastor FJ, Guarro J. Interlaboratory evaluation of the E-test for antifungal susceptibility testing of dermatophytes. Med Mycol 2003; 41: 125-130.
6. Hudson MM. Antifungal resistance and over-the-counter availability in the UK: a current perspective. J Antimicrobiol Chemother 2001; 48: 345-350.
7. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistence to terbinafine. Antimicrobiol Agents Chemother 2003; 47: 82-86.
8. Sanabria JA, Bonifaz A, Saúl A. Terbinafine en el tratamiento de micosis superficiales. Dermatología Rev Mex 1990; 34: 189-198.
9. Santos DA, Hamdan S. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006; 44: 357-362.
10. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
11. Silva-Barros ME, Hamdam S. Determination of susceptibility/resistance to antifungal drugs of Trichophyton mentagrophytes isolates by a macrodilution method. Can J Microbiol 2005; 51: 983-987.
12. Szekely A, Jonson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing molds. J Clin Microbiol 1999; 37: 1480-1483.
13. Vesell ES. On the significance of the host factors that affect drug disposition. Clin Pharmacol Ther 1982; 3:1-7.